바이오인

So, what will the future hold for pharmaceuticals in India and how should MNCs approach the Indian pharmaceutical market?

 

Each of these questions portends a different future for the Indian pharmaceutical market and a different opportunity for MNCs, yet these questions don't have clear answers. How can MNCs build a strategy without a better idea of which assumptions will prove to be correct? If you bet on the wrong assumptions, you could risk catastrophe. If you wait until the answers are known, it might be too late. The uncertainty could paralyze a company or lead it to develop a compromise strategy that won’t expose it to ruin but won’t achieve breakthrough results. The challenge is not to look for a superior prediction of the future because it doesn’t exist. The challenge is to manage the strategic risks embedded in these questions.

 

In this new point of view article, learn how the use of Strategic Flexibility ? the combination of scenario planning with real options to provide a framework for identifying uncertainties and developing the options needed ? may help MNCs contemplating entry into or expansion in India reduce the unknown to a manageable number of outcomes. Also learn how the Strategic Flexibility Framework could be applied to four plausible scenarios for the Indian pharmaceutical market in 2015.